Kevin Forrest

5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US.

Semprus BioSciences, headquartered in Cambridge, Massachusetts, is a venture-backed biomedical company with a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies. Their innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology. Their current focus is to enable the first permanently dual-functional (anti-colonization and anti-thrombogenic) vascular access catheter with a single surface modification. Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform - which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of their Semprus Surfaces™, a permanent non-leaching biomaterial modification to the device surface, their technology is expected to vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. They have assembled a world class product development team - scientists, industry executives and clinical experts - who specialize in reducing such complications at the confluence of the human body and implantable devices.

EPIRUS Biopharmaceuticals, Inc. develops monoclonal antibodies. It offers pharmaceutical products. The company is headquartered in Boston, MA.

Variation Biotechnologies (US), Inc. develops and manufactures vaccines for infectious diseases. It is dedicated to the innovative formulation, development and delivery of safe and effective vaccines that expand and enhance vaccine protection in both established and emerging markets. The company was founded by David E. Anderson and Adam Buckley in 2001 and is headquartered in Boston, MA.

VBI Vaccines, Inc. is a biopharmaceutical company. It engages in the development of eVLP vaccine platform for the design of (e) virus-like-particle vaccines that closely mimic the target virus. The company also involves in the development of thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. VBI Vaccines was founded on July 25, 2014 and is headquartered in Cambridge, MA.

Marcadia Biotech, Inc. develops therapeutic products for diabetes and obesity. It is a biopharmaceutical company focuses on developing a broad portfolio of drug candidates for treatment of diabetes and obesity. The company was founded in 2005 and is headquartered in Carmel, IN.

Expansion Therapeutics, Inc. manufactures pharmaceutical products. The company is headquartered in Del Mar, CA.

The American company is focused on developing gene therapies to treat muscle and heart diseases using adeno-associated virus (AAV) technology. Kate Therapeutics is applying novel technology platforms to address the limitations of current gene therapies, including tissue-specific delivery and gene regulation. The company's breakthroughs have the potential to improve the efficacy and safety of gene therapies and enable the pursuit of a broader set of targets that are otherwise difficult to drug with current technologies. The company was founded by Eric Wang, Mark Fielden, Alan H. Beggs, Sharif Tabebordbar, Kevin M. Forrest, and Kevin M. Forrest has been the CEO since incorporation.